Today, more and more clinical trials companies like Veristat develop drugs by adopting modern clinical trial models over the traditional trial models. As such, these trials play a huge role in research. And they allow medical researchers to determine the efficacy and safety products they want to deliver on the market.
Since many trials are being improved to satisfy the needs of both the pharmaceutical companies and patients, the long-term practicality raises many concerns. Also, industry stakeholders are fast exploring avenues like virtual clinical trials to help bring quick response and ease to the challenges arising from forced early adoption. Why then are virtual clinical trials a game-changer in drug development? Let’s explore this further.
Data Capture Proficiency
Thanks to technology, the ability to collect data instantaneously is an advantage to remote monitoring. The intricacies of adverse reporting, navigating contracts, remote management, recruitment, and EMR are housed in sophisticated technology. Capturing virtual data includes end-to-end remote machine management and therefore should include things like, Cloud computing, Adaptation for patient use, easy-to-navigate qualitative kit, How physicians manage care and the analysis of field data to integrate into other data-capturing solutions.
The arrival of the pandemic threatened the possibility of continuing clinical trials. Fortunately, researchers developed fast adaptation methods to help keep clinical trials active and even credible. As such, data-driven tools like AI, social media, and even remote patient monitoring have proven to not only work but they are working even better than anticipated. That means, today, clinical trial continuity is rooted in technology. However, it also rests strongly on flexibility. To address the arising concerns, there’s the use of in-home nursing or aids, direct patient contact, as well as safeguarding patients home environments by providing adequate power sources and supplies.
Typically, clinical trials cost equal to millions of dollars with some running to about a decade to completion. The average costs for each patient participant are stated to cost about $41, 117 as per a report accepted by the U. S. Health and Human Services Department. Even then, Virtual clinical trials have helped reduce the average costs of delivering a drug on the market through:
- Streamlining patient visits
- Shorter enrollment periods
- Accelerated gathering of data and accuracy
- Decrease of investigator fees
- Trial drop-out rates reduction
- Lesser need for onsite data management
Facilitates reaching of more diverse patients populations
There’s a focus on the underrepresentation of the minority groups during clinical trials. And the FDA has even issued a regulation document to help close the gap. The agreement is to help improve the statistics with the help of technology and the expanded eligibility criteria. Also, the limitations that come with generalized burden to stakeholders and logistics are greatly lifted after going virtual. This then helps bridge both services as well as the convenience of monitoring.
From what we’ve seen, you could assume that the future is in the continuance of doing virtual recruitment and clinical trials. This also means that this approach will result in the development of more sophisticated devices and tools. This will be aimed at streamlining the whole process for key stakeholders.